Optiscan Imaging completes beta phase testing of cloud-based telepathology platform

Small Caps07-29

Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2455506487?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/07/Optiscan-Imaging-ASX-OIL-Prolucid-Technologies-platform.jpg","is_english":true,"pubTime":"2024-07-29 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2455506487","market":"us","top_or_hot":-1,"title":"Optiscan Imaging completes beta phase testing of cloud-based telepathology platform","media":"Small Caps","content":"<div>\n<p>Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies.\n...</p>\n\n<a href=\"https://smallcaps.com.au/optiscan-imaging-beta-testing-cloud-based-telepathology-platform/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optiscan Imaging completes beta phase testing of cloud-based telepathology platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptiscan Imaging completes beta phase testing of cloud-based telepathology platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-29 10:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/optiscan-imaging-beta-testing-cloud-based-telepathology-platform/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies.\n...</p>\n\n<a href=\"https://smallcaps.com.au/optiscan-imaging-beta-testing-cloud-based-telepathology-platform/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://smallcaps.com.au/optiscan-imaging-beta-testing-cloud-based-telepathology-platform/","article_id":"2455506487","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/07/Optiscan-Imaging-ASX-OIL-Prolucid-Technologies-platform.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455506487","pubTimestamp":1722220289,"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"Commercial-stage medical technology company Optiscan Imaging  has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies.The platform is believed to represent a significant advancement in digital pathology, enabling real-time collaboration on patient imaging sessions and allowing remote users to make immediate and informed decisions.The phase tested its functionality and opened the way for enhanced patient imaging in remote scenarios.The new platform leverages Optiscan’s confocal imaging technology to natively generate digital pathology data and empower remote pathologists and clinicians to collaborate in real-time during imaging sessions.“This platform is a potential game-changer for rural and remote patients who have traditionally lacked access to dedicated pathology expertise and immediate decision-making from clinicians and pathologists,” she said.“It demonstrates that we have met our goal of creating a cloud-conne","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","OIL.AU":"OPTISCAN IMAGING LIMITED"},"translate_title":"Optiscan Imaging完成基于云的心灵病理学平台的beta阶段测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OIL.AU":1},"content_text":"Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies.\nThe platform is believed to represent a significant advancement in digital pathology, enabling real-time collaboration on patient imaging sessions and allowing remote users to make immediate and informed decisions.\nThe phase tested its functionality and opened the way for enhanced patient imaging in remote scenarios.\nLeveraging technology\nThe new platform leverages Optiscan’s confocal imaging technology to natively generate digital pathology data and empower remote pathologists and clinicians to collaborate in real-time during imaging sessions.\nIt streamlines the telepathology workflow with secure device-to-cloud connectivity and a dedicated web portal so that remote pathologists can seamlessly join the imaging session on a computer terminal and communicate their observations directly with the clinician.\nThe platform also allows for offline review and annotation of captured images, with detailed report generation planned for a future iteration.\nPatient data privacy and secure user access are protected, with the architecture adhering to the highest regulatory and cybersecurity standards.\nInformed decision-making\nOptiscan managing director Dr Camile Farah said the technology facilitates fast and informed decision-making at the point of care and can ultimately improve patient outcomes.\n“This platform is a potential game-changer for rural and remote patients who have traditionally lacked access to dedicated pathology expertise and immediate decision-making from clinicians and pathologists,” she said.\n“Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting health care professionals.”\nBridging the gap\nDr Farah said the beta testing was a milestone achievement in the platform’s development.\n“It demonstrates that we have met our goal of creating a cloud-connected telepathology platform which bridges the gap between imaging and remote diagnostics, providing a seamless, secure and efficient workflow,” she said.\n“With the beta testing phase now complete, we have ramped up efforts to create a commercial version of the platform and look forward to its implementation in clinical settings.”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455506487"}